{"product_id":"pt-141","title":"PT-141","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eA melanocortin receptor agonist studied for sexual function, CNS signaling, and neuroendocrine pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is PT-141?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePT-141 (bremelanotide) is a synthetic cyclic heptapeptide that acts as an agonist of the melanocortin-4 receptor (MC4R). Originally derived from melanotan II, PT-141’s mechanism operates through the central nervous system rather than the vascular system. It received regulatory approval in 2019 under the brand name Vyleesi for a specific clinical application.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eHistory\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePT-141 emerged from research into melanocortin peptides conducted at the University of Arizona in the 1990s. Researchers studying melanotan II (a synthetic tanning peptide) observed unexpected effects on sexual arousal during clinical trials, leading to the development of PT-141 as a more targeted compound. Bremelanotide was developed by Palatin Technologies and ultimately received regulatory approval in 2019 after extensive clinical trials demonstrated its CNS-mediated mechanism of action.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"10MG","offer_id":44884422197293,"sku":null,"price":69.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/PT-141.png?v=1777402919","url":"https:\/\/protocolaminos.com\/products\/pt-141","provider":"Protocol Aminos","version":"1.0","type":"link"}